| Biocon Revenue up by 21 pc for Q1 at Rs 212 cr; PAT Rs 39 cr |
 |
| Bangalore, July 19 (UNI) Biotech leader Biocon today reported a consolidated revenue of Rs 212 crore for the first quarter of the current fiscal, despite delayed entry of Simvastatin and Pravastatin into the US market on account of 180 days exclusivity granted. |
2006/7/31
Biocon Revenue up by 21 pc for Q1 at Rs 212 cr; PAT Rs 39 cr
訂閱：
張貼留言 (Atom)
沒有留言:
張貼留言